IDEAYA Biosciences, Inc. Financing Cash Flow
IDEAYA Biosciences, Inc. (IDYA) reported Financing Cash Flow of $360.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $359.21M, a 29709.96% increase year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.18M, a 95.48% decline year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.13M, a 22.63% decline year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $301.00K, a 99.89% decline year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $29.78M, a 95.60% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $677.55M, a 86.80% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $362.72M, a 273.30% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $97.17M, a 33.20% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $359.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $360.39M 10-Q · filed 2026-08-04 | $362.52M derived: sum of 3 quarters · filed 2026-08-04 | $362.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-05 | $3.31M derived: sum of 2 quarters · filed 2026-05-05 | $3.61M derived: sum of 3 quarters · filed 2026-05-05 | $4.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.43M derived: sum of 2 quarters · filed 2026-02-17 | $3.64M derived: sum of 3 quarters · filed 2026-08-04 | $29.78M 10-K · filed 2026-02-17 |
| 2025-09-30 | $301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.51M derived: sum of 2 quarters · filed 2026-08-04 | $27.65M 10-Q · filed 2025-11-04 | $30.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $27.35M 10-Q · filed 2026-08-04 | $30.10M derived: sum of 3 quarters · filed 2026-08-04 | $316.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $26.14M 10-Q · filed 2026-05-05 | $28.90M derived: sum of 2 quarters · filed 2026-05-05 | $315.40M derived: sum of 3 quarters · filed 2026-05-05 | $354.58M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $289.26M derived: sum of 2 quarters · filed 2026-02-17 | $328.44M derived: sum of 3 quarters · filed 2026-02-17 | $677.55M 10-K · filed 2026-02-17 |
| 2024-09-30 | $286.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $325.69M derived: sum of 2 quarters · filed 2025-11-04 | $674.80M 10-Q · filed 2025-11-04 | $815.69M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $39.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $388.29M 10-Q · filed 2025-08-05 | $529.19M derived: sum of 3 quarters · filed 2026-02-17 | $557.02M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $349.11M 10-Q · filed 2025-05-06 | $490.00M derived: sum of 2 quarters · filed 2026-02-17 | $517.84M derived: sum of 3 quarters · filed 2026-02-17 | $708.90M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $140.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $168.73M derived: sum of 2 quarters · filed 2026-02-17 | $359.79M derived: sum of 3 quarters · filed 2026-02-17 | $362.72M 10-K · filed 2026-02-17 |
| 2023-09-30 | $27.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $218.90M derived: sum of 2 quarters · filed 2024-11-04 | $221.82M 10-Q · filed 2024-11-04 | $222.15M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $191.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $193.99M 10-Q · filed 2024-08-06 | $194.31M derived: sum of 3 quarters · filed 2025-02-18 | $290.01M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $2.93M 10-Q · filed 2024-05-07 | $3.25M derived: sum of 2 quarters · filed 2025-02-18 | $98.95M derived: sum of 3 quarters · filed 2025-02-18 | $99.44M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $96.02M derived: sum of 2 quarters · filed 2025-02-18 | $96.51M derived: sum of 3 quarters · filed 2025-02-18 | $97.17M 10-K · filed 2025-02-18 |
| 2022-09-30 | $95.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $96.19M derived: sum of 2 quarters · filed 2023-11-07 | $96.84M 10-Q · filed 2023-11-07 | $97.53M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $491.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.14M 10-Q · filed 2023-08-10 | $1.83M derived: sum of 3 quarters · filed 2024-02-20 | $88.61M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $653.00K 10-Q · filed 2023-05-09 | $1.34M derived: sum of 2 quarters · filed 2024-02-20 | $88.12M derived: sum of 3 quarters · filed 2024-02-20 | $104.10M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $688.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $87.46M derived: sum of 2 quarters · filed 2024-02-20 | $103.45M derived: sum of 3 quarters · filed 2024-02-20 | $145.45M 10-K · filed 2024-02-20 |
| 2021-09-30 | $86.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $102.76M derived: sum of 2 quarters · filed 2022-11-08 | $144.77M 10-Q · filed 2022-11-08 | $151.72M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $15.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $57.99M 10-Q · filed 2022-08-15 | $64.94M derived: sum of 3 quarters · filed 2023-03-07 | $92.01M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $42.00M 10-Q · filed 2022-05-10 | $48.95M derived: sum of 2 quarters · filed 2023-03-07 | $76.02M derived: sum of 3 quarters · filed 2023-03-07 | $170.72M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $34.02M derived: sum of 2 quarters · filed 2023-03-07 | $128.72M derived: sum of 3 quarters · filed 2023-03-07 | $128.75M 10-K · filed 2023-03-07 |
| 2020-09-30 | $27.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $121.77M derived: sum of 2 quarters · filed 2021-11-15 | $121.80M 10-Q · filed 2021-11-15 | $121.84M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | $94.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $94.73M 10-Q · filed 2021-08-10 | $94.77M derived: sum of 3 quarters · filed 2022-03-18 | $94.50M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | $34.00K 10-Q · filed 2021-05-10 | $72.00K derived: sum of 2 quarters · filed 2022-03-18 | -$204.00K derived: sum of 3 quarters · filed 2022-03-18 | $51.47M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$238.00K derived: sum of 2 quarters · filed 2022-03-18 | $51.44M derived: sum of 3 quarters · filed 2022-03-18 | $50.61M 10-K · filed 2022-03-18 |
| 2019-09-30 | -$276.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $51.40M derived: sum of 2 quarters · filed 2020-11-12 | $50.57M 10-Q · filed 2020-11-12 | $50.49M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $51.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $50.85M 10-Q · filed 2020-08-12 | $50.77M derived: sum of 3 quarters · filed 2021-03-23 | $50.81M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | -$826.00K 10-Q · filed 2020-05-12 | -$903.00K derived: sum of 2 quarters · filed 2021-03-23 | -$862.00K derived: sum of 3 quarters · filed 2021-03-23 | |
| 2018-12-31 | -$77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$36.00K derived: sum of 2 quarters · filed 2021-03-23 | $105.38M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $105.45M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $105.41M 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $17.49M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |